[go: up one dir, main page]

AR066955A1 - Derivados de 7- alquinil -1,8- naftiridonas, su preparacion y su aplicacion en terapeutica - Google Patents

Derivados de 7- alquinil -1,8- naftiridonas, su preparacion y su aplicacion en terapeutica

Info

Publication number
AR066955A1
AR066955A1 ARP080102478A ARP080102478A AR066955A1 AR 066955 A1 AR066955 A1 AR 066955A1 AR P080102478 A ARP080102478 A AR P080102478A AR P080102478 A ARP080102478 A AR P080102478A AR 066955 A1 AR066955 A1 AR 066955A1
Authority
AR
Argentina
Prior art keywords
alkyl group
preparation
group
application
hydrogen atom
Prior art date
Application number
ARP080102478A
Other languages
English (en)
Inventor
Antoine Alam
Francoise Bono
Olivier Duclos
Cort Gary Mc
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of AR066955A1 publication Critical patent/AR066955A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Quinoline Compounds (AREA)

Abstract

Se refiere a los compuestos que responden a la formula (1) en la que R1 y R2, representan independientemente el uno del otro: un átomo de hidrogeno, un grupo alquilo C1-7 sustituido opcionalmente con uno o varios grupos alcoxi, R3, representa un grupo alquilo C1-7; R4 representa un átomo de hidrogeno, un grupo alquilo C1-4; Y representa un grupo alcoxi C1-4, un grupo -NRR', -O(CH2)n-C(O)-NRR' en los que R y R' son tales como se definen a continuacion y n es un numero entero igual a 1 o 2; Rö representa un grupo alquilo C1-4; y R y R' representan independientemente el uno del otro un átomo de hidrogeno, un grupo -CO-alquilo C1-C4 o un grupo -COORö, en el que Rö es tal como se ha definido anteriormente Procedimiento de preparacion y aplicacion en terapéutica en enfermedades donde está implicada VEGFR-3, cáncer, metástasis, artrosis, psoriasis.
ARP080102478A 2007-06-13 2008-06-11 Derivados de 7- alquinil -1,8- naftiridonas, su preparacion y su aplicacion en terapeutica AR066955A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0704193A FR2917413B1 (fr) 2007-06-13 2007-06-13 Derives de 7-alkynyl-1,8-naphthyridones, leur preparation et leur application en therapeutique

Publications (1)

Publication Number Publication Date
AR066955A1 true AR066955A1 (es) 2009-09-23

Family

ID=38961501

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080102478A AR066955A1 (es) 2007-06-13 2008-06-11 Derivados de 7- alquinil -1,8- naftiridonas, su preparacion y su aplicacion en terapeutica

Country Status (28)

Country Link
US (2) US8263614B2 (es)
EP (1) EP2158194B1 (es)
JP (1) JP5346337B2 (es)
KR (1) KR20100019507A (es)
CN (1) CN101815715B (es)
AR (1) AR066955A1 (es)
AT (1) ATE509923T1 (es)
AU (1) AU2008274100B2 (es)
BR (1) BRPI0813809B1 (es)
CA (1) CA2690349C (es)
CO (1) CO6150157A2 (es)
CY (1) CY1111748T1 (es)
DK (1) DK2158194T3 (es)
EA (1) EA016552B1 (es)
ES (1) ES2366629T3 (es)
FR (1) FR2917413B1 (es)
HR (1) HRP20110550T1 (es)
IL (1) IL202677A (es)
IN (1) IN2009KN04279A (es)
MA (1) MA31674B1 (es)
ME (1) ME00957B (es)
MX (1) MX2009013514A (es)
MY (1) MY146939A (es)
NZ (1) NZ581883A (es)
PL (1) PL2158194T3 (es)
PT (1) PT2158194E (es)
SI (1) SI2158194T1 (es)
WO (1) WO2009007536A2 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2917412B1 (fr) * 2007-06-13 2009-08-21 Sanofi Aventis Sa Derives de 7-alkynyl, 1,8-naphthyridones, leur preparation et leur application en therapeutique
CA2708264C (en) * 2007-12-10 2018-07-03 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of antecedent hematologic disorders
FR2933700B1 (fr) 2008-07-08 2010-07-30 Sanofi Aventis Derives de pyridino-pyridinones, leur preparation et leur application en therapeutique
FR2952934B1 (fr) * 2009-11-23 2012-06-22 Sanofi Aventis Derives de pyridino-pyridinones, leur preparation et leur application en therapeutique
FR2954943B1 (fr) * 2010-01-07 2013-03-01 Sanofi Aventis Derives de pyridino-pyridinones arylsulfonamides, leur preparation et leur application en therapeutique
FR2955109B1 (fr) * 2010-01-08 2012-09-07 Sanofi Aventis Derives de 5-oxo-5,8-dihydro-pyrido[2, 3-d]pyrimidine, leur preparation et leur application en therapeutique
WO2012009097A1 (en) * 2010-06-17 2012-01-19 Cytokinetics, Inc. Methods of treating lung disease
WO2013072882A1 (en) * 2011-11-18 2013-05-23 Actelion Pharmaceuticals Ltd 2 -amino- 1, 8 -naphthyridine-3 -carboxamide derivatives as antimicrobial agents
CN116509854B (zh) * 2023-04-26 2025-05-23 浙江省中医院、浙江中医药大学附属第一医院（浙江省东方医院） 一种萘啶酮衍生物的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0841927B1 (en) 1995-08-02 2004-01-28 Darwin Discovery Limited Quinolones and their therapeutic use
WO1999038867A1 (en) 1998-01-29 1999-08-05 Suntory Limited 1-cycloalkyl-1,8-naphthyridin-4-one derivatives with phosphodiesterase iv inhibitory activity
DE19826050A1 (de) * 1998-06-12 1999-12-16 Bayer Ag Verfahren zur Herstellung von Chinolon- und Naphthyridoncarbonsäuren und deren Ester
BR0209485A (pt) 2001-05-08 2004-07-06 Schering Ag Antranilamidapiridinamidas seletivas como inibidores vegfr-2 e vegfr-3
CA2447765C (en) 2001-05-24 2011-01-25 Merck Frosst Canada & Co./Merck Frosst Canada & Cie 1-biaryl-1,8-napthyridin-4-one phosphodiesterase-4 inhibitors
US7148357B2 (en) 2002-07-31 2006-12-12 Schering Ag VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridines
US20070254877A1 (en) * 2004-06-02 2007-11-01 Takada Pharmaceutical Company Limited Indole Derivative and Use for Treatment of Cancer
FR2917412B1 (fr) * 2007-06-13 2009-08-21 Sanofi Aventis Sa Derives de 7-alkynyl, 1,8-naphthyridones, leur preparation et leur application en therapeutique

Also Published As

Publication number Publication date
WO2009007536A2 (fr) 2009-01-15
BRPI0813809B1 (pt) 2021-05-25
CN101815715A (zh) 2010-08-25
ES2366629T3 (es) 2011-10-24
CY1111748T1 (el) 2015-10-07
SI2158194T1 (sl) 2011-10-28
US8586602B2 (en) 2013-11-19
US20100144782A1 (en) 2010-06-10
MY146939A (en) 2012-10-15
NZ581883A (en) 2011-05-27
US20120238598A1 (en) 2012-09-20
WO2009007536A3 (fr) 2009-03-19
DK2158194T3 (da) 2011-09-12
AU2008274100B2 (en) 2013-07-11
BRPI0813809A2 (pt) 2020-02-04
MX2009013514A (es) 2010-01-27
FR2917413A1 (fr) 2008-12-19
MA31674B1 (fr) 2010-09-01
CN101815715B (zh) 2014-10-08
PT2158194E (pt) 2011-08-17
KR20100019507A (ko) 2010-02-18
WO2009007536A8 (fr) 2010-01-07
IN2009KN04279A (es) 2015-08-28
HRP20110550T1 (hr) 2011-09-30
PL2158194T3 (pl) 2011-10-31
CA2690349A1 (fr) 2009-01-15
ATE509923T1 (de) 2011-06-15
JP2010529179A (ja) 2010-08-26
IL202677A (en) 2014-12-31
FR2917413B1 (fr) 2009-08-21
IL202677A0 (en) 2010-06-30
AU2008274100A1 (en) 2009-01-15
HK1143590A1 (en) 2011-01-07
CO6150157A2 (es) 2010-04-20
EP2158194B1 (fr) 2011-05-18
CA2690349C (fr) 2015-11-24
US8263614B2 (en) 2012-09-11
EA201070010A1 (ru) 2010-06-30
EP2158194A2 (fr) 2010-03-03
JP5346337B2 (ja) 2013-11-20
ME00957B (me) 2012-06-20
EA016552B1 (ru) 2012-05-30

Similar Documents

Publication Publication Date Title
AR066955A1 (es) Derivados de 7- alquinil -1,8- naftiridonas, su preparacion y su aplicacion en terapeutica
UY30804A1 (es) Derivados de nicotinamida, sus sales y solvatos, composiciones farmacéuticas conteniendolas y aplicaciones
CL2017002609A1 (es) Compuestos derivados de pirazolopiridina hidrogenadas, inhibidores p2x7, composición farmacéutica que los comprende; proceso de preparación de estos; y su uso en el tratamiento de enfermedades oseas, sns, cardiovasculares, entre otras (divisional de cl 2655-2015)
CR10643A (es) DERIVADOS DE 2-ARIL-6-FENIL-IMIDAZOL[1,2-a]PIRIDINAS, SU PREPARACION Y SU APLICACION EN TERAPEUTICA
ECSP11011470A (es) Nuevos derivados de pirimidina y sus usos en el tratamiento del cáncer y otras enfermedades
MX343264B (es) Ciertas amino-piridazinas, composiciones de las mismas y metodos de uso de los mismos.
CU20160030A7 (es) Compuestos éteres de arilo yútiles para tratar cancer de célula renal
CU20110204A7 (es) Compuestos 1-cianoetilheterociclilcarboxamida sustituidos 750
AR087328A1 (es) Derivados de imidazo[1,2-b]piridazina e imidazo[4,5-b]piridina como inhibidores de jak
PE20151448A1 (es) Compuestos de tiazolcarboxamidas y piridinacarboxamida utiles como inhibidores de quinasa pim
BR112016007427A2 (pt) compostos de pirazol-amida e usos dos mesmos
UY30938A1 (es) Derivados de nicotinamida, sales y solvatos farmacéuticamente aceptables, composiciones y aplicaciones.
NO20085216L (no) Benzimidazoler og deres anvendelse i behandlingen av diabetes
CR20130099A (es) Composiciones que contienen un insecticida de piripiropeno y una base
CO6351789A2 (es) Derivados de carbamatos de alquiltiazoles, su preparacion y su aplicacion en terapeutica
UY32801A (es) Nuevos derivados dihidroindolonas, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
MY194004A (en) 4 -substituted benzoxaborole compounds and uses thereof
UY32635A (es) Derivados de bis-(sulfonilamino) en terapia 735
BR112015027164A2 (pt) novos compostos com tripla atividade de trombólise, antitrombótica e neutralização de radical, e sua síntese, nanoestrutura e uso
AR072880A1 (es) Derivados nitrogenados de la pancratistatina
MX2018010177A (es) Compuestos de 6,7-dihidro-5h-pirazolo[5,1-b][1,3]oxazina-2-carboxa mida.
CL2023002783A1 (es) Compuestos para regular inmunidad entrenada y sus métodos de uso
CL2023000772A1 (es) Compuestos heterocíclicos de heteroarilo y usos de los mismos
AR079543A1 (es) Derivados de amino-heteroarilo
UY29485A1 (es) Esteres alquílicos de aminoalcoholes cíclicos, composiciones farmacéuticas que los contienen, procedimientos de preparación y aplicaciones

Legal Events

Date Code Title Description
FB Suspension of granting procedure